Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean dextrosa and fructose and phosphoricum acid?
Displaying drugs 2301 - 2325 of 15091 in total

Spiramycin

Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium. Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in...
Approved
Matched Description: … Toxoplasma gondii and Cryptosporidium. ... Resistant organisms include Enterobacteria, pseudomonads, and moulds. ... a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and …
Matched Categories: … spiramycin and metronidazole ... Macrolides, Lincosamides and Streptogramins …

Normethadone

Normethadone is used as an opioid antitussive in combination with DB11610. It is marketed in Canada by Valeant under the tradename Cophylac.
Approved
Illicit
Matched Categories: … Cough and Cold Preparations ... Opium Alkaloids and Derivatives …

Benznidazole

Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.
Approved
Investigational
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …

Activated charcoal

Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high...
Approved
Matched Description: … oral ingestion of certain medications or poisons by absorbing most drugs and toxins. ... It is used as a gastric decontaminant and emergency medication to treat poisonings following excessive ... passed over its surface to make a fine network of pores, producing a material with large surface area and …
Matched Categories: … Antacids and Adsorbents ... Alimentary Tract and Metabolism …

Granisetron

A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Approved
Investigational
Matched Description: … A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant …
Matched Categories: … Alimentary Tract and Metabolism ... Antiemetics and Antinauseants …

Sodium aurotiosulfate

Approved
Experimental
Matched Categories: … Antiinflammatory and Antirheumatic Products …

Anthrax immune globulin human

Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing...
Approved
Matched Description: … polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and ... to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Garlic

Garlic allergenic extract is used in allergenic testing.
Approved
Nutraceutical
Matched Categories: … Herbs and Natural Products …

Papaya

Papaya allergenic extract is used in allergenic testing.
Approved
Matched Categories: … Herbs and Natural Products …

Diphemanil

Approved
Vet approved
Withdrawn
Matched Categories: … Alimentary Tract and Metabolism ... diphemanil and psycholeptics …

Danicopan

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Matched Description: … [A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. ... hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and ... Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Potassium aspartate

Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …

Nitazoxanide

Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of...
Approved
Investigational
Vet approved
Matched Description: … proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic ... Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and ... children and may also be considered in the treatment of illnesses caused by other protozoa or helminths …
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …

Atracurium besylate

A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Approved
Matched Description: … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for …

Asciminib

Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein which serves as a driver of CML proliferation in most patients with the disease....
Approved
Investigational
Matched Description: … those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those ... Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into ... in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

L-arginine

Approved
Nutraceutical
Matched Categories: … Amino Acids, Peptides, and Proteins …

Practolol

A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
Approved

Belatacept

Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Investigational
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Axicabtagene ciloleucel

Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express...
Approved
Matched Description: … It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular ... kill cancer cells, and are infused back into the patient. ... collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Deucravacitinib

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … triglyceride levels and liver and kidney dysfunction. ... [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines ... nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Vespula squamosa venom protein

Vespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Sotatercept

Sotatercept is an activin signalling inhibitor. It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension...
Approved
Investigational
Matched Description: … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Efbemalenograstim alfa

Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration.[L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim...
Approved
Matched Description: … GC-627-05 in the US and Europe respectively. ... thus reducing the severity and duration of neutropenia. ... A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Protamine sulfate

Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps the only viable option for reversing the anticoagulant effect of heparin use for over 77 years [A174778,...
Approved
Matched Description: … kidney tissue damage, and anaphylactic reaction, amongst others [A174778, L5371]. ... reversal predominantly via the formation of an inactive complex between the anionic nature of heparin and ... potential range in reversing all parenteral anticoagulants are sometimes considered high and limited …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Lonafarnib

Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384,...
Approved
Investigational
Matched Description: … treatment for HGPS and other related progeroid laminopathies. ... [A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed ... [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Displaying drugs 2301 - 2325 of 15091 in total